Imagine facing pleural mesothelioma, a tough lung cancer, and finding out that your previous treatments aren't working anymore. This situation is a harsh reality for many patients, as the disease can be stubborn and resistant to standard therapies like chemotherapy and immunotherapy. Now, there's a new glimmer of hope: a drug called ivonescimab is being tested for patients whose cancer has returned after these treatments. In this study, 38 patients will receive ivonescimab every three weeks for up to two years. The goal is to see if this drug can help control the disease better than previous options. If it works, it could mean fewer patients experiencing disease progression and more time with their loved ones. However, it's important to remember that this is still in the testing phase, and we won't know the full results for a while. Patients should stay informed and discuss all available options with their healthcare team as this research unfolds.
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
Plain Language Summary
What this means for you:
A new drug may offer renewed hope for patients with returning pleural mesothelioma, opening doors to better treatment options. What this means for you:
A new drug may offer renewed hope for patients with returning pleural mesothelioma, opening doors to better treatment options. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Pleural Mesotheliomas
Intervention(s): Ivonescimab (DRUG)
Multicentre, open-label, single arm phase II study for patients with PM previously treated by immunotherapy and standard chemotherapy. 38 patients will be given second or third-line treatment with ivonescimab 20mg/kg every 3 weeks.
An estimated 38 patients will be enrolled in approximately 20 centres. Patients will be treated for a maximum of 2 years, until disease progression, unacceptable toxicity, withdrawal of consent or another discontinuation criterion is met.
The null hypothesis is disease control rate (DCR) at 12 weeks ≤ 30%. The alternative hypothesis is DCR ≥ 55% at 12 weeks.
Primary Outcome(s): To assess the therapeutic value of the bispecific antibody anti-VEGF / anti-PD-1 ivonescimab as 2nd/3rd line treatment in relapsing PM patients
Enrollment: 38 (ESTIMATED)
Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Start: 2025-06-30 | Primary Completion: 2026-03-24